Auriga Partners logo

Auriga Partners

Europe, Ile-de-France, France, Paris

Description

Auriga Partners is a well-established independent venture capital firm based in Paris, France, founded in 1998. With a strong focus on early-stage investments, the firm primarily targets the Information Technology sector, encompassing areas such as software, internet, telecommunications, semiconductors, and electronics. Their investment thesis extends to cutting-edge domains like deep tech, artificial intelligence, cybersecurity, SaaS, fintech, and the Internet of Things, demonstrating a commitment to innovation across various digital frontiers.

Auriga Partners typically deploys initial investment tickets ranging from €1 million to €5 million (approximately $1.08 million to $5.4 million, based on recent exchange rates). This initial capital is often followed by significant additional funding, potentially reaching up to €10 million per company, supporting portfolio companies through various growth stages. Their approach emphasizes active partnership with founders, leveraging their extensive network and operational expertise to help scale promising technology ventures.

Over its more than two decades of operation, Auriga Partners has built a robust track record, having supported over 80 companies since its inception. The firm has successfully managed multiple funds, with a total funding amount of approximately $191.6 million across four distinct vehicles. This long-standing presence in the European tech ecosystem has enabled them to contribute significantly to the development of numerous innovative companies, leading to a strong history of successful exits and value creation for their limited partners.

Investor Profile

Auriga Partners has backed more than 162 startups, with 0 new investments in the last 12 months alone. The firm has led 32 rounds, about 20% of its total and boasts 40 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series B, Series A, Series Unknown rounds (top funding stages).
  • Majority of deals are located in France, United States, Switzerland.
  • Strong thematic focus on Biotechnology, Health Care, Pharmaceutical.
  • Typical check size: $1.1M – $5.4M.

Stage Focus

  • Series B (28%)
  • Series A (23%)
  • Series Unknown (16%)
  • Series C (13%)
  • Series D (5%)
  • Post Ipo Equity (4%)
  • Seed (3%)
  • Series E (3%)
  • Private Equity (1%)
  • Corporate Round (1%)

Country Focus

  • France (65%)
  • United States (17%)
  • Switzerland (6%)
  • United Kingdom (4%)
  • Sweden (2%)
  • Pakistan (2%)
  • Israel (2%)
  • Belgium (1%)

Industry Focus

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Manufacturing
  • Medical
  • Software
  • Medical Device
  • Therapeutics
  • Information Technology
  • Enterprise Software
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Auriga Partners frequently co-invest with?

Wellington Partners
Europe, Bayern, Germany, Munich
Co-Investments: 7
Innovation Capital
Europe, Ile-de-France, France, Paris
Co-Investments: 11
Omnes Capital
Europe, Ile-de-France, France, Paris
Co-Investments: 12
Ventech
Europe, Ile-de-France, France, Paris
Co-Investments: 12
Andera Partners
Europe, Ile-de-France, France, Paris
Co-Investments: 13
Sofinnova Partners
Europe, Ile-de-France, France, Paris
Co-Investments: 9
Idinvest Partners
Europe, Ile-de-France, France, Paris
Co-Investments: 12
Bpifrance
Europe, Ile-de-France, France, Maisons-alfort
Co-Investments: 10
123Venture
Europe, Ile-de-France, France, Paris
Co-Investments: 7
Siparex Groupe
Europe, Ile-de-France, France, Paris
Co-Investments: 13

Which angels does Auriga Partners often collaborate with?

Shared Deals: 1
JL
Europe, France
Shared Deals: 1
AS
Europe, Midi-Pyrenees, France, Toulouse
Shared Deals: 1

What are some of recent deals done by Auriga Partners?

Exeliom

Dijon, Bourgogne, France

Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs.

BiopharmaBiotechnologyHealth CarePharmaceutical
Series AJun 30, 2023
Amount Raised: $8,733,148
Patrowl

Paris, Ile-de-France, France

Patrowl helps you to identify and harden you External Security Posture with realtime and continuous Pentest-as-a-Service solution

Cyber SecurityPenetration Testing
SeedJun 24, 2022
Amount Raised: $2,111,199
Vade Secure

Hem, Picardie, France

Vade Secure offers an email filtering service against phishing, malware, spear phishing, and spam.

Cyber SecurityEmailEnterprise SoftwareInformation TechnologySecuritySoftware
Series UnknownMay 31, 2022
Amount Raised: $30,055,560
Exeliom

Dijon, Bourgogne, France

Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs.

BiopharmaBiotechnologyHealth CarePharmaceutical
Series AJul 6, 2018
Amount Raised: $8,227,454
Flash Therapeutics

Toulouse, Midi-Pyrenees, France

Flash Therapeutics is a new gene therapy company developing gene and cell-based therapies by leveraging its proprietary lentiviral platform.

BiotechnologyHealth CareMedical
Private EquityMay 16, 2018
Amount Raised: $3,898,889
EnobraQ

Ramonville-saint-agne, Midi-Pyrenees, France

EnobraQ is a Toulouse-based biotechnology company.

BiotechnologyChemical
SeedApr 10, 2018
Amount Raised: $3,585,235
Pherecydes Pharma

Romainville, Ile-de-France, France

Pherecydes Pharma Operator of an innovative biotechnologies company created to develop personalized phage therapy.

BiotechnologyHealth CareMedical Device
Series BJan 16, 2018
Amount Raised: $10,675,921
aveni

Massy, Ile-de-France, France

Aveni offers novel metallization technology that enables the future of semiconductor manufacturing.

ElectronicsManufacturingSemiconductor
Series BOct 24, 2017
Amount Raised: $10,466,463
Vectalys

Toulouse, Midi-Pyrenees, France

Vectalys help scientists understand cellular and molecular mechanisms in order to discover new drugs and therapies.

BiotechnologyManufacturingWellness
Series UnknownJun 13, 2017
Amount Raised: $1,681,407
VitaDX

Paris, Ile-de-France, France

VitaDX develops a non-invasive solution for early bladder cancer diagnosis.

Artificial Intelligence (AI)BiotechnologyOncology
SeedJun 6, 2017
Amount Raised: $1,803,359